2-氯-4-(甲基氨基)烟腈 | 676601-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-4-(甲基氨基)烟腈
• 英文名称: 2-chloro-4-methylaminopyridine-3-nitrile
• 英文别名: 2-chloro-4-(methylamino)pyridine-3-carbonitrile；2-chloro-4-methylamino-nicotinonitrile；2-Chloro-4-(methylamino)nicotinonitrile
• CAS: 676601-68-6
• 化学式: C₇H₆ClN₃
• mdl: MFCD08272048
• 分子量: 167.598
• InChiKey: KVEWZFUOTWMHQC-UHFFFAOYSA-N

物化性质

• 沸点：
  355.9±42.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯-4-(甲基氨基)烟腈 在 palladium on activated charcoal 氨 、 氢气 、 三乙胺盐酸盐 、 sodium hydride 、 三乙胺 、 3-氯苯甲酸 、 三氯氧磷 作用下， 以 乙醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 62.0h， 生成 5-chloro-1-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-methyl-9H-2,4,6,9-tetraaza-fluorene
  参考文献：
  名称：

  Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance

  摘要：

  In our continued effort to identify selective MRP1 modulators, we have developed two novel templates, 3 and 4, through rational drug design by identifying the key pharmacophore interaction at the 7-position of the pyrrolopyrimidine template 1. Further synthesis and SAR work on these novel templates gave a number of potent MRP1 modulators with great selectivity against Pgp. Additional studies to reduce the CYP3A4 inhibition are also reported. Several compounds of these classes were subjected to in vivo xenograft studies and in vivo efficacies were demonstrated.

  DOI：

  10.1021/jm0310129
• 作为产物：
  描述：

  2,4-二氯-3-氰基吡啶 、 甲胺 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.08h， 以283 mg的产率得到2-氯-4-(甲基氨基)烟腈
  参考文献：
  名称：

  FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS

  摘要：

  本发明提供了一种具有CaMKII抑制作用的融合杂环芳基化合物，预计可用作心脏疾病（特别是儿茶酚胺多形性室性心动过速、术后房颤、心力衰竭、致命性心律失常）的预防或治疗药物。本发明涉及一种由以下式（I）表示的化合物：其中每个符号如描述中定义，或其药学上可接受的盐。

  公开号：

  US20220098207A1

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018103058A1

  公开（公告）日：2018-06-14

  Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

  公式（I'）的化合物及其使用和制备方法，以及包含公式（I'）化合物的组合物。
• [EN] POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] COMPOSÉS POLYCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017100662A1

  公开（公告）日：2017-06-15

  The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).

  本公开涉及化合物的公式（I）作为Bruton激酶抑制剂及其制备，以及包含化合物的公式（I）的组合物。
• INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20170283431A1

  公开（公告）日：2017-10-05

  The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.
• Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance
  作者：Shouming Wang、Nan Chi Wan、John Harrison、Warren Miller、Irina Chuckowree、Sukhjit Sohal、Timothy C. Hancox、Stewart Baker、Adrian Folkes、Francis Wilson、Deanne Thompson、Simon Cocks、Hayley Farmer、Anthony Boyce、Caroline Freathy、Jan Broadbridge、John Scott、Paul Depledge、Richard Faint、Prakash Mistry、Peter Charlton

  DOI：10.1021/jm0310129

  日期：2004.3.1

  In our continued effort to identify selective MRP1 modulators, we have developed two novel templates, 3 and 4, through rational drug design by identifying the key pharmacophore interaction at the 7-position of the pyrrolopyrimidine template 1. Further synthesis and SAR work on these novel templates gave a number of potent MRP1 modulators with great selectivity against Pgp. Additional studies to reduce the CYP3A4 inhibition are also reported. Several compounds of these classes were subjected to in vivo xenograft studies and in vivo efficacies were demonstrated.
• FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US20220098207A1

  公开（公告）日：2022-03-31

  The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有CaMKII抑制作用的融合杂环芳基化合物，预计可用作心脏疾病（特别是儿茶酚胺多形性室性心动过速、术后房颤、心力衰竭、致命性心律失常）的预防或治疗药物。本发明涉及一种由以下式（I）表示的化合物：其中每个符号如描述中定义，或其药学上可接受的盐。